NASDAQ: IRIX
Iridex Corp Stock

$1.13-0.04 (-3.42%)
Updated Jun 18, 2026
IRIX Price
$1.13
Fair Value Price
N/A
Market Cap
$19.67M
52 Week Low
$0.87
52 Week High
$1.65
P/E
-5.95x
P/B
4.16x
P/S
0.32x
PEG
N/A
Dividend Yield
N/A
Revenue
$52.58M
Earnings
-$3.28M
Gross Margin
36%
Operating Margin
-6.03%
Profit Margin
-6.2%
Debt to Equity
4.98
Operating Cash Flow
-$2M
Beta
0.84
Next Earnings
Aug 18, 2026
Ex-Dividend
N/A
Next Dividend
N/A

IRIX Overview

IRIDEX Corporation is a medical technology firm specializing in ophthalmology. They develop and supply advanced therapeutic laser systems, various delivery instruments, and essential consumable tools designed to address vision-threatening ocular conditions. Their product portfolio includes several laser consoles, each tailored for specific eye conditions. The Cyclo G6 system is specifically engineered for glaucoma treatment. For ailments like diabetic macular edema and other retinal pathologies, IRIDEX provides the IQ 532 and IQ 577 laser photocoagulation systems. Furthermore, the OcuLight series, encompassing models such as TX, SL, SLx, GL, and GLx, offers solutions for managing severe retinal issues like proliferative diabetic retinopathy, macular holes, and retinal tears or detachments. Beyond laser consoles, the company also manufactures specialized delivery instruments. These include the TxCell scanning laser delivery system, which empowers clinicians with multi-spot pattern scanning capabilities. A unique slit lamp adapter enables practitioners to integrate standard slit lamps into their diagnostic and therapeutic workflows. Additionally, a laser indirect ophthalmoscope is available for interventions targeting peripheral retinal disorders. IRIDEX's offerings extend to various probes. The MicroPulse P3 Probe, when coupled with the Cyclo G6 laser system, facilitates MicroPulse transscleral laser therapy. For managing uncontrolled glaucoma, the G-Probe is employed, while both the G-Probe and G-Probe Illuminate are utilized in procedures addressing refractory glaucoma. The EndoProbe product line supports a range of vitrectomy procedures. Their diverse client base spans ophthalmology professionals, academic and research hospitals, government healthcare facilities, specialized surgical centers, general hospitals, veterinary clinics, and private medical practices. Product distribution is handled via an internal and independent sales network across the United States, supplemented by independent distributors for its international markets. Originally incorporated in 1989 as IRIS Medical Instruments, Inc., the company adopted the name IRIDEX Corporation in November 1995. Its corporate headquarters are situated in Mountain View, California.

Zen Rating

Our proven quant model uses 115 proprietary factors, including AI, to determine IRIX's potential to beat the market

Zen Rating Component Grades

N/A
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.

Industry: Medical Device

Industry Rating
C
IRIX
Ranked
Unranked of 93

Top Ranked Stocks in Industry

Name / TickerPriceZen Rating
$8.71A
$38.68A
$26.62A
View Top Medical Device Stocks

Be the first to know about important IRIX news, forecast changes, insider trades & much more!

IRIX News

Overview

Due Diligence Score

Industry Average (29)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how IRIX scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

IRIX is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
IRIX is poor value based on its book value relative to its share price (4.16x), compared to the US Medical Devices industry average (2.95x)
P/B vs Industry Valuation
IRIX is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more IRIX due diligence checks available for Premium users.

Valuation

IRIX price to earnings (PE)

For valuing profitable companies with steady earnings

Company
-5.95x
Industry
20.08x
Market
9.47x

IRIX price to book (PB)

For valuing companies that are loss-making or have lots of physical asset

Company
4.16x
Industry
2.95x
IRIX is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation

IRIX's financial health

Profit margin

Revenue
$11.8M
Net Income
-$524.0k
Profit Margin
-4.4%
IRIX's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
IRIX's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials

Assets to liabilities

Assets
$28.3M
Liabilities
$23.5M
Debt to equity
4.98
IRIX's short-term assets ($24.58M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
IRIX's short-term assets ($24.58M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
IRIX's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
IRIX's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
-$1.3M
Investing
-$101.0k
Financing
-$1.0k
IRIX's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

IRIX vs Medical Device Stocks

TickerZen RatingMarket Cap1d %P/EP/B
IRIX$19.67M-3.42%-5.95x4.16x
LFWD$19.45M-1.00%-0.36x3.09x
PLSM$22.43M-5.61%-4.38x0.84x
AIMD$15.60M-10.29%-0.63x2.74x
HIND$15.23M-0.46%-0.03x1.89x

Iridex Stock FAQ

What is Iridex's quote symbol?

(NASDAQ: IRIX) Iridex trades on the NASDAQ under the ticker symbol IRIX. Iridex stock quotes can also be displayed as NASDAQ: IRIX.

If you're new to stock investing, here's how to buy Iridex stock.

What is the 52 week high and low for Iridex (NASDAQ: IRIX)?

(NASDAQ: IRIX) Iridex's 52-week high was $1.65, and its 52-week low was $0.87. It is currently -31.43% from its 52-week high and 30.03% from its 52-week low.

How much is Iridex stock worth today?

(NASDAQ: IRIX) Iridex currently has 17,406,518 outstanding shares. With Iridex stock trading at $1.13 per share, the total value of Iridex stock (market capitalization) is $19.67M.

Iridex stock was originally listed at a price of $7.63 in Dec 31, 1997. If you had invested in Iridex stock at $7.63, your return over the last 28 years would have been -85.18%, for an annualized return of -6.59% (not including any dividends or dividend reinvestments).

How much is Iridex's stock price per share?

(NASDAQ: IRIX) Iridex stock price per share is $1.13 today (as of Jun 18, 2026).

What is Iridex's Market Cap?

(NASDAQ: IRIX) Iridex's market cap is $19.67M, as of Jun 21, 2026.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Iridex's market cap is calculated by multiplying IRIX's current stock price of $1.13 by IRIX's total outstanding shares of 17,406,518.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.